167 related articles for article (PubMed ID: 10914735)
1. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Delaney CA; Wang LZ; Kyle S; White AW; Calvert AH; Curtin NJ; Durkacz BW; Hostomsky Z; Newell DR
Clin Cancer Res; 2000 Jul; 6(7):2860-7. PubMed ID: 10914735
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.
Bowman KJ; White A; Golding BT; Griffin RJ; Curtin NJ
Br J Cancer; 1998 Nov; 78(10):1269-77. PubMed ID: 9823965
[TBL] [Abstract][Full Text] [Related]
3. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
[TBL] [Abstract][Full Text] [Related]
4. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.
Boulton S; Kyle S; Durkacz BW
Carcinogenesis; 1999 Feb; 20(2):199-203. PubMed ID: 10069454
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
[TBL] [Abstract][Full Text] [Related]
6. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).
Griffin RJ; Srinivasan S; Bowman K; Calvert AH; Curtin NJ; Newell DR; Pemberton LC; Golding BT
J Med Chem; 1998 Dec; 41(26):5247-56. PubMed ID: 9857092
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors.
Boulton S; Pemberton LC; Porteous JK; Curtin NJ; Griffin RJ; Golding BT; Durkacz BW
Br J Cancer; 1995 Oct; 72(4):849-56. PubMed ID: 7547230
[TBL] [Abstract][Full Text] [Related]
8. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.
Tentori L; Portarena I; Vernole P; De Fabritiis P; Madaio R; Balduzzi A; Roy R; Bonmassar E; Graziani G
Cancer Chemother Pharmacol; 2001 Apr; 47(4):361-9. PubMed ID: 11345654
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.
Tentori L; Portarena I; Bonmassar E; Graziani G
Cell Death Differ; 2001 May; 8(5):457-69. PubMed ID: 11423906
[TBL] [Abstract][Full Text] [Related]
10. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
White AW; Almassy R; Calvert AH; Curtin NJ; Griffin RJ; Hostomsky Z; Maegley K; Newell DR; Srinivasan S; Golding BT
J Med Chem; 2000 Nov; 43(22):4084-97. PubMed ID: 11063605
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
12. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
Calabrese CR; Almassy R; Barton S; Batey MA; Calvert AH; Canan-Koch S; Durkacz BW; Hostomsky Z; Kumpf RA; Kyle S; Li J; Maegley K; Newell DR; Notarianni E; Stratford IJ; Skalitzky D; Thomas HD; Wang LZ; Webber SE; Williams KJ; Curtin NJ
J Natl Cancer Inst; 2004 Jan; 96(1):56-67. PubMed ID: 14709739
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors.
White AW; Curtin NJ; Eastman BW; Golding BT; Hostomsky Z; Kyle S; Li J; Maegley KA; Skalitzky DJ; Webber SE; Yu XH; Griffin RJ
Bioorg Med Chem Lett; 2004 May; 14(10):2433-7. PubMed ID: 15109627
[TBL] [Abstract][Full Text] [Related]
14. Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: effects on NAD metabolism and DNA repair.
Boulton S; Kyle S; Durkacz BW
Br J Cancer; 1997; 76(7):845-51. PubMed ID: 9328141
[TBL] [Abstract][Full Text] [Related]
15. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
17. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
Curtin NJ; Wang LZ; Yiakouvaki A; Kyle S; Arris CA; Canan-Koch S; Webber SE; Durkacz BW; Calvert HA; Hostomsky Z; Newell DR
Clin Cancer Res; 2004 Feb; 10(3):881-9. PubMed ID: 14871963
[TBL] [Abstract][Full Text] [Related]
18. Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.
Sabisz M; Wesierska-Gadek J; Skladanowski A
Biochem Pharmacol; 2010 May; 79(10):1387-97. PubMed ID: 20067769
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Cimmino G; Pepe S; Laus G; Chianese M; Prece D; Penitente R; Quesada P
Pharmacol Res; 2007 Jan; 55(1):49-56. PubMed ID: 17127074
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
Curtin NJ; Bowman KJ; Turner RN; Huang B; Loughlin PJ; Calvert AH; Golding BT; Griffin RJ; Newell DR
Br J Cancer; 1999 Aug; 80(11):1738-46. PubMed ID: 10468290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
